Volition(US:VNRX) Prnewswire·2024-10-09 12:00Core Insights - The upcoming webinar on October 21, 2024, will focus on the extensive studies regarding the use of Nu.Q® NETs in sepsis management, involving over 3000 patients and more than 14,000 samples [1][2] - Volition's technology aims to enhance clinical practice in sepsis management by quantifying H3.1 nucleosomes, which are critical in predicting organ failure [3] Company Overview - Volition is a multinational company dedicated to advancing epigenetics and developing cost-effective blood tests for diagnosing and monitoring diseases, including cancer and sepsis [5][6][7] - The company emphasizes the importance of early diagnosis and monitoring to improve patient outcomes and quality of life [7] Technology and Research - The Nu.Q® NETs technology quantifies circulating H3.1 nucleosomes in the bloodstream, serving as a surrogate marker for Neutrophil Extracellular Traps (NETs), which can lead to severe health issues when elevated [3] - Research findings from independent studies will be highlighted in the webinar, showcasing the potential of Nu.Q® NETs in clinical settings [2][3] Event Details - The webinar will be hosted by Soo Romanoff from Edison Group and will include insights from Volition's Chief Medical Officer and Chief Commercial Officer [4] - Registration for the event is available, and it will be recorded for on-demand access [4]